A study done by Center for Disease Control and Prevention (CDC) of the United States, released on Wednesday (25/1), shows that vaccination against Covid-19 with updated booster doses of Pfizer or Moderna helped prevent almost half of symptomatic cases of the disease after infection by the XBB subvariant by Ômicron, the largest in circulation in the country.

This is one of the first studies to prove the effectiveness of bivalent vaccines in the real world. It shows that immunizations designed to offer greater protection against BA.4 and BA.5 subvariants worked similarly against XBB and XBB.1.5 infections.

The study was based on a review of Covid-19 cases registered in the country between December 1, 2022 and January 13, 2023.

It shows that the vaccine was 52% effective in preventing infections against BA.5 and 48% against XBB and XBB.1.5 among adults aged 18 to 49 years. Among the elderly, the effectiveness dropped to 37% and 43%, against the respective subvariants.

Advertising by Metrópoles 1 partner
Advertising by Metrópoles 2 partner
Advertising by Metrópoles 3 partner
Advertising by Metrópoles 4 partner

0

“Today we have additional evidence to show that these updated vaccines are protecting people against the latest variants of Covid-19,” Brendan Jackson, head of pandemic response, said at a news conference.

According to him, the data also show that the bivalent vaccine reduced the risk of death from Covid-19 by more than two times compared to vaccinated people who did not receive the updated booster and reduced the risk of death by approximately 13 times among those who did not. vaccinated.

Get news from metropolises on your Telegram and stay on top of everything! Just access the channel: https://t.me/metropolesurgente.

California18

Welcome to California18, your number one source for Breaking News from the World. We’re dedicated to giving you the very best of News.

Leave a Reply